|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RPSA |
Gene summary for RPSA |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RPSA | Gene ID | 3921 |
| Gene name | ribosomal protein SA | |
| Gene Alias | 37LRP | |
| Cytomap | 3p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000028 | UniProtAcc | A0A0C4DG17 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 3921 | RPSA | GSM4909277 | Human | Breast | Precancer | 1.55e-02 | -6.85e-01 | 0.0177 |
| 3921 | RPSA | GSM4909280 | Human | Breast | Precancer | 1.80e-04 | -6.18e-01 | 0.0305 |
| 3921 | RPSA | GSM4909281 | Human | Breast | IDC | 2.64e-10 | 2.19e-01 | 0.21 |
| 3921 | RPSA | GSM4909286 | Human | Breast | IDC | 7.25e-101 | 5.11e-01 | 0.1081 |
| 3921 | RPSA | GSM4909290 | Human | Breast | IDC | 3.03e-03 | 1.62e-01 | 0.2096 |
| 3921 | RPSA | GSM4909292 | Human | Breast | IDC | 6.70e-09 | -7.35e-01 | 0.1236 |
| 3921 | RPSA | GSM4909293 | Human | Breast | IDC | 1.01e-20 | -2.42e-01 | 0.1581 |
| 3921 | RPSA | GSM4909294 | Human | Breast | IDC | 8.65e-04 | 3.66e-02 | 0.2022 |
| 3921 | RPSA | GSM4909296 | Human | Breast | IDC | 1.78e-10 | 1.45e-01 | 0.1524 |
| 3921 | RPSA | GSM4909297 | Human | Breast | IDC | 3.62e-10 | -1.01e-01 | 0.1517 |
| 3921 | RPSA | GSM4909301 | Human | Breast | IDC | 1.02e-08 | -2.93e-01 | 0.1577 |
| 3921 | RPSA | GSM4909304 | Human | Breast | IDC | 4.11e-60 | 4.12e-01 | 0.1636 |
| 3921 | RPSA | GSM4909305 | Human | Breast | IDC | 4.66e-04 | 1.83e-01 | 0.0436 |
| 3921 | RPSA | GSM4909311 | Human | Breast | IDC | 2.43e-25 | -1.14e-01 | 0.1534 |
| 3921 | RPSA | GSM4909312 | Human | Breast | IDC | 7.49e-09 | 1.91e-01 | 0.1552 |
| 3921 | RPSA | GSM4909316 | Human | Breast | IDC | 2.16e-02 | 1.12e-01 | 0.21 |
| 3921 | RPSA | GSM4909319 | Human | Breast | IDC | 3.22e-47 | -2.41e-01 | 0.1563 |
| 3921 | RPSA | GSM4909320 | Human | Breast | IDC | 9.27e-07 | -2.62e-02 | 0.1575 |
| 3921 | RPSA | GSM4909321 | Human | Breast | IDC | 2.68e-06 | 7.44e-02 | 0.1559 |
| 3921 | RPSA | brca2 | Human | Breast | Precancer | 2.94e-08 | -1.28e-01 | -0.024 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004225428 | Skin | cSCC | ribosome biogenesis | 206/4864 | 299/18723 | 3.33e-55 | 1.04e-51 | 206 |
| GO:000218129 | Skin | cSCC | cytoplasmic translation | 127/4864 | 148/18723 | 4.83e-53 | 7.57e-50 | 127 |
| GO:007182629 | Skin | cSCC | ribonucleoprotein complex subunit organization | 140/4864 | 227/18723 | 5.54e-30 | 3.16e-27 | 140 |
| GO:002261829 | Skin | cSCC | ribonucleoprotein complex assembly | 136/4864 | 220/18723 | 2.60e-29 | 1.25e-26 | 136 |
| GO:001603229 | Skin | cSCC | viral process | 211/4864 | 415/18723 | 7.04e-28 | 2.76e-25 | 211 |
| GO:004227429 | Skin | cSCC | ribosomal small subunit biogenesis | 59/4864 | 73/18723 | 1.39e-22 | 2.90e-20 | 59 |
| GO:001905829 | Skin | cSCC | viral life cycle | 157/4864 | 317/18723 | 1.29e-19 | 1.88e-17 | 157 |
| GO:004225529 | Skin | cSCC | ribosome assembly | 44/4864 | 61/18723 | 5.84e-14 | 3.81e-12 | 44 |
| GO:004440328 | Skin | cSCC | biological process involved in symbiotic interaction | 126/4864 | 290/18723 | 6.39e-11 | 2.97e-09 | 126 |
| GO:005170129 | Skin | cSCC | biological process involved in interaction with host | 91/4864 | 203/18723 | 4.30e-09 | 1.45e-07 | 91 |
| GO:000002829 | Skin | cSCC | ribosomal small subunit assembly | 16/4864 | 19/18723 | 1.77e-07 | 3.93e-06 | 16 |
| GO:005212629 | Skin | cSCC | movement in host environment | 76/4864 | 175/18723 | 3.81e-07 | 7.55e-06 | 76 |
| GO:0019693112 | Skin | cSCC | ribose phosphate metabolic process | 146/4864 | 396/18723 | 9.28e-07 | 1.68e-05 | 146 |
| GO:000675324 | Skin | cSCC | nucleoside phosphate metabolic process | 176/4864 | 497/18723 | 1.55e-06 | 2.62e-05 | 176 |
| GO:0046390111 | Skin | cSCC | ribose phosphate biosynthetic process | 79/4864 | 190/18723 | 1.86e-06 | 3.10e-05 | 79 |
| GO:000911724 | Skin | cSCC | nucleotide metabolic process | 173/4864 | 489/18723 | 2.03e-06 | 3.35e-05 | 173 |
| GO:0072521112 | Skin | cSCC | purine-containing compound metabolic process | 150/4864 | 416/18723 | 2.88e-06 | 4.54e-05 | 150 |
| GO:0006163112 | Skin | cSCC | purine nucleotide metabolic process | 140/4864 | 396/18723 | 1.93e-05 | 2.27e-04 | 140 |
| GO:007252218 | Skin | cSCC | purine-containing compound biosynthetic process | 78/4864 | 200/18723 | 3.44e-05 | 3.74e-04 | 78 |
| GO:190129310 | Skin | cSCC | nucleoside phosphate biosynthetic process | 95/4864 | 256/18723 | 5.21e-05 | 5.31e-04 | 95 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
| hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
| hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301034 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
| hsa0517134 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
| hsa0301044 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517144 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0301054 | Breast | DCIS | Ribosome | 82/846 | 167/8465 | 8.69e-39 | 1.40e-36 | 1.03e-36 | 82 |
| hsa0517154 | Breast | DCIS | Coronavirus disease - COVID-19 | 86/846 | 232/8465 | 2.42e-29 | 1.56e-27 | 1.15e-27 | 86 |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0301020 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa03010110 | Cervix | CC | Ribosome | 85/1267 | 167/8465 | 3.17e-28 | 5.14e-26 | 3.04e-26 | 85 |
| hsa0301025 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0301035 | Cervix | HSIL_HPV | Ribosome | 80/459 | 167/8465 | 9.61e-58 | 2.82e-55 | 2.28e-55 | 80 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RPSA | SNV | Missense_Mutation | novel | c.774G>T | p.Gln258His | p.Q258H | protein_coding | deleterious(0.01) | possibly_damaging(0.866) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| RPSA | SNV | Missense_Mutation | novel | c.797N>G | p.Gln266Arg | p.Q266R | protein_coding | deleterious(0.03) | benign(0.019) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RPSA | SNV | Missense_Mutation | rs771423193 | c.566N>A | p.Arg189His | p.R189H | protein_coding | tolerated(0.33) | benign(0.007) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RPSA | SNV | Missense_Mutation | novel | c.774N>T | p.Gln258His | p.Q258H | protein_coding | deleterious(0.01) | possibly_damaging(0.866) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RPSA | SNV | Missense_Mutation | novel | c.774N>T | p.Gln258His | p.Q258H | protein_coding | deleterious(0.01) | possibly_damaging(0.866) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| RPSA | SNV | Missense_Mutation | novel | c.80G>A | p.Gly27Asp | p.G27D | protein_coding | tolerated(0.12) | benign(0.139) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RPSA | SNV | Missense_Mutation | novel | c.575N>A | p.Gly192Asp | p.G192D | protein_coding | deleterious(0.04) | benign(0.088) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RPSA | SNV | Missense_Mutation | c.690G>T | p.Glu230Asp | p.E230D | protein_coding | tolerated(0.08) | benign(0.159) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| RPSA | SNV | Missense_Mutation | novel | c.221N>C | p.Val74Ala | p.V74A | protein_coding | deleterious(0.01) | probably_damaging(0.98) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| RPSA | SNV | Missense_Mutation | novel | c.127A>C | p.Ser43Arg | p.S43R | protein_coding | deleterious(0.04) | benign(0.154) | TCGA-QF-A5YS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 3921 | RPSA | NA | PMID25747044-Compound-miRNA | |||
| 3921 | RPSA | NA | MITOXANTRONE | MITOXANTRONE | 8630412 | |
| 3921 | RPSA | NA | DOXORUBICIN | DOXORUBICIN | 11493465 | |
| 3921 | RPSA | NA | DAUNORUBICIN | DAUNORUBICIN | 15161018 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |